Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level

Wim van den Brink, Giovanni Addolorato, Henri Jean Aubin, Amine Benyamina, Fabio Caputo, Maurice Dematteis, Antoni Gual, Otto Michael Lesch, Karl Mann, Icro Maremmani, David Nutt, François Paille, Pascal Perney, Jürgen Rehm, Michel Reynaud, Nicolas Simon, Bo Söderpalm, Wolfgang H. Sommer, Henriette Walter, Rainer Spanagel

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Medication development for alcohol relapse prevention or reduction of consumption is highly challenging due to methodological issues of pharmacotherapy trials. Existing approved medications are only modestly effective with many patients failing to benefit from these therapies. Therefore, there is a pressing need for other effective treatments with a different mechanism of action, especially for patients with very high (VH) drinking risk levels (DRL) because this is the most severely affected population of alcohol use disorder patients. Life expectancy of alcohol-dependent patients with a VH DRL is reduced by 22 years compared with the general population and approximately 90 000 alcohol-dependent subjects with a VH DRL die prematurely each year in the EU (Rehm et al.). A promising new medication for this population is sodium oxybate, a compound that acts on GABAB receptors and extrasynaptic GABAA receptors resulting in alcohol-mimetic effects. In this article, a European expert group of alcohol researchers and clinicians summarizes data (a) from published trials, (b) from two new—as yet unpublished—large clinical trials (GATE 2 (n = 314) and SMO032 (n = 496), (c) from post hoc subgroup analyses of patients with different WHO-defined DRLs and (d) from multiple meta-analyses. These data provide convergent evidence that sodium oxybate is effective especially in a subgroup of alcohol-dependent patients with VH DRLs. Depending on the study, abstinence rates are increased up to 34 percent compared with placebo with risk ratios up to 6.8 in favor of sodium oxybate treatment. These convergent data are supported by the clinical use of sodium oxybate in Austria and Italy for more than 25 years. Sodium oxybate is the sodium salt of γ-hydroxybutyric acid that is also used as a recreational (street) drug suggestive of abuse potential. However, a pharmacovigilance database of more than 260 000 alcohol-dependent patients treated with sodium oxybate reported very few adverse side effects and only few cases of abuse. We therefore conclude that sodium oxybate is an effective, well-tolerated and safe treatment for withdrawal and relapse prevention treatment, especially in alcohol-dependent patients with VH DRL.

Original languageEnglish
Pages (from-to)969-986
Number of pages18
JournalAddiction Biology
Volume23
Issue number4
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Sodium Oxybate
Drinking
Alcohols
Safety
Street Drugs
Secondary Prevention
Population
Hydroxybutyrates
Pharmacovigilance
Therapeutics
Austria
GABA-A Receptors
Life Expectancy
Italy
Meta-Analysis
Salts
Sodium
Odds Ratio
Placebos
Research Personnel

Keywords

  • acamprosate, nalrexone, nalmefene, heavy drinking
  • alcohol dependence
  • alcoholism
  • drinking risk level
  • gamma-hydroxybutyric acid
  • GHB
  • sodium oxybate

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology
  • Psychiatry and Mental health

Cite this

van den Brink, W., Addolorato, G., Aubin, H. J., Benyamina, A., Caputo, F., Dematteis, M., ... Spanagel, R. (2018). Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. Addiction Biology, 23(4), 969-986. https://doi.org/10.1111/adb.12645

Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. / van den Brink, Wim; Addolorato, Giovanni; Aubin, Henri Jean; Benyamina, Amine; Caputo, Fabio; Dematteis, Maurice; Gual, Antoni; Lesch, Otto Michael; Mann, Karl; Maremmani, Icro; Nutt, David; Paille, François; Perney, Pascal; Rehm, Jürgen; Reynaud, Michel; Simon, Nicolas; Söderpalm, Bo; Sommer, Wolfgang H.; Walter, Henriette; Spanagel, Rainer.

In: Addiction Biology, Vol. 23, No. 4, 01.07.2018, p. 969-986.

Research output: Contribution to journalArticle

van den Brink, W, Addolorato, G, Aubin, HJ, Benyamina, A, Caputo, F, Dematteis, M, Gual, A, Lesch, OM, Mann, K, Maremmani, I, Nutt, D, Paille, F, Perney, P, Rehm, J, Reynaud, M, Simon, N, Söderpalm, B, Sommer, WH, Walter, H & Spanagel, R 2018, 'Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level', Addiction Biology, vol. 23, no. 4, pp. 969-986. https://doi.org/10.1111/adb.12645
van den Brink, Wim ; Addolorato, Giovanni ; Aubin, Henri Jean ; Benyamina, Amine ; Caputo, Fabio ; Dematteis, Maurice ; Gual, Antoni ; Lesch, Otto Michael ; Mann, Karl ; Maremmani, Icro ; Nutt, David ; Paille, François ; Perney, Pascal ; Rehm, Jürgen ; Reynaud, Michel ; Simon, Nicolas ; Söderpalm, Bo ; Sommer, Wolfgang H. ; Walter, Henriette ; Spanagel, Rainer. / Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. In: Addiction Biology. 2018 ; Vol. 23, No. 4. pp. 969-986.
@article{ed41d3e38db24cb09eb472ad6213e985,
title = "Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level",
abstract = "Medication development for alcohol relapse prevention or reduction of consumption is highly challenging due to methodological issues of pharmacotherapy trials. Existing approved medications are only modestly effective with many patients failing to benefit from these therapies. Therefore, there is a pressing need for other effective treatments with a different mechanism of action, especially for patients with very high (VH) drinking risk levels (DRL) because this is the most severely affected population of alcohol use disorder patients. Life expectancy of alcohol-dependent patients with a VH DRL is reduced by 22 years compared with the general population and approximately 90 000 alcohol-dependent subjects with a VH DRL die prematurely each year in the EU (Rehm et al.). A promising new medication for this population is sodium oxybate, a compound that acts on GABAB receptors and extrasynaptic GABAA receptors resulting in alcohol-mimetic effects. In this article, a European expert group of alcohol researchers and clinicians summarizes data (a) from published trials, (b) from two new—as yet unpublished—large clinical trials (GATE 2 (n = 314) and SMO032 (n = 496), (c) from post hoc subgroup analyses of patients with different WHO-defined DRLs and (d) from multiple meta-analyses. These data provide convergent evidence that sodium oxybate is effective especially in a subgroup of alcohol-dependent patients with VH DRLs. Depending on the study, abstinence rates are increased up to 34 percent compared with placebo with risk ratios up to 6.8 in favor of sodium oxybate treatment. These convergent data are supported by the clinical use of sodium oxybate in Austria and Italy for more than 25 years. Sodium oxybate is the sodium salt of γ-hydroxybutyric acid that is also used as a recreational (street) drug suggestive of abuse potential. However, a pharmacovigilance database of more than 260 000 alcohol-dependent patients treated with sodium oxybate reported very few adverse side effects and only few cases of abuse. We therefore conclude that sodium oxybate is an effective, well-tolerated and safe treatment for withdrawal and relapse prevention treatment, especially in alcohol-dependent patients with VH DRL.",
keywords = "acamprosate, nalrexone, nalmefene, heavy drinking, alcohol dependence, alcoholism, drinking risk level, gamma-hydroxybutyric acid, GHB, sodium oxybate",
author = "{van den Brink}, Wim and Giovanni Addolorato and Aubin, {Henri Jean} and Amine Benyamina and Fabio Caputo and Maurice Dematteis and Antoni Gual and Lesch, {Otto Michael} and Karl Mann and Icro Maremmani and David Nutt and Fran{\cc}ois Paille and Pascal Perney and J{\"u}rgen Rehm and Michel Reynaud and Nicolas Simon and Bo S{\"o}derpalm and Sommer, {Wolfgang H.} and Henriette Walter and Rainer Spanagel",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/adb.12645",
language = "English",
volume = "23",
pages = "969--986",
journal = "Addiction Biology",
issn = "1355-6215",
publisher = "Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level

AU - van den Brink, Wim

AU - Addolorato, Giovanni

AU - Aubin, Henri Jean

AU - Benyamina, Amine

AU - Caputo, Fabio

AU - Dematteis, Maurice

AU - Gual, Antoni

AU - Lesch, Otto Michael

AU - Mann, Karl

AU - Maremmani, Icro

AU - Nutt, David

AU - Paille, François

AU - Perney, Pascal

AU - Rehm, Jürgen

AU - Reynaud, Michel

AU - Simon, Nicolas

AU - Söderpalm, Bo

AU - Sommer, Wolfgang H.

AU - Walter, Henriette

AU - Spanagel, Rainer

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Medication development for alcohol relapse prevention or reduction of consumption is highly challenging due to methodological issues of pharmacotherapy trials. Existing approved medications are only modestly effective with many patients failing to benefit from these therapies. Therefore, there is a pressing need for other effective treatments with a different mechanism of action, especially for patients with very high (VH) drinking risk levels (DRL) because this is the most severely affected population of alcohol use disorder patients. Life expectancy of alcohol-dependent patients with a VH DRL is reduced by 22 years compared with the general population and approximately 90 000 alcohol-dependent subjects with a VH DRL die prematurely each year in the EU (Rehm et al.). A promising new medication for this population is sodium oxybate, a compound that acts on GABAB receptors and extrasynaptic GABAA receptors resulting in alcohol-mimetic effects. In this article, a European expert group of alcohol researchers and clinicians summarizes data (a) from published trials, (b) from two new—as yet unpublished—large clinical trials (GATE 2 (n = 314) and SMO032 (n = 496), (c) from post hoc subgroup analyses of patients with different WHO-defined DRLs and (d) from multiple meta-analyses. These data provide convergent evidence that sodium oxybate is effective especially in a subgroup of alcohol-dependent patients with VH DRLs. Depending on the study, abstinence rates are increased up to 34 percent compared with placebo with risk ratios up to 6.8 in favor of sodium oxybate treatment. These convergent data are supported by the clinical use of sodium oxybate in Austria and Italy for more than 25 years. Sodium oxybate is the sodium salt of γ-hydroxybutyric acid that is also used as a recreational (street) drug suggestive of abuse potential. However, a pharmacovigilance database of more than 260 000 alcohol-dependent patients treated with sodium oxybate reported very few adverse side effects and only few cases of abuse. We therefore conclude that sodium oxybate is an effective, well-tolerated and safe treatment for withdrawal and relapse prevention treatment, especially in alcohol-dependent patients with VH DRL.

AB - Medication development for alcohol relapse prevention or reduction of consumption is highly challenging due to methodological issues of pharmacotherapy trials. Existing approved medications are only modestly effective with many patients failing to benefit from these therapies. Therefore, there is a pressing need for other effective treatments with a different mechanism of action, especially for patients with very high (VH) drinking risk levels (DRL) because this is the most severely affected population of alcohol use disorder patients. Life expectancy of alcohol-dependent patients with a VH DRL is reduced by 22 years compared with the general population and approximately 90 000 alcohol-dependent subjects with a VH DRL die prematurely each year in the EU (Rehm et al.). A promising new medication for this population is sodium oxybate, a compound that acts on GABAB receptors and extrasynaptic GABAA receptors resulting in alcohol-mimetic effects. In this article, a European expert group of alcohol researchers and clinicians summarizes data (a) from published trials, (b) from two new—as yet unpublished—large clinical trials (GATE 2 (n = 314) and SMO032 (n = 496), (c) from post hoc subgroup analyses of patients with different WHO-defined DRLs and (d) from multiple meta-analyses. These data provide convergent evidence that sodium oxybate is effective especially in a subgroup of alcohol-dependent patients with VH DRLs. Depending on the study, abstinence rates are increased up to 34 percent compared with placebo with risk ratios up to 6.8 in favor of sodium oxybate treatment. These convergent data are supported by the clinical use of sodium oxybate in Austria and Italy for more than 25 years. Sodium oxybate is the sodium salt of γ-hydroxybutyric acid that is also used as a recreational (street) drug suggestive of abuse potential. However, a pharmacovigilance database of more than 260 000 alcohol-dependent patients treated with sodium oxybate reported very few adverse side effects and only few cases of abuse. We therefore conclude that sodium oxybate is an effective, well-tolerated and safe treatment for withdrawal and relapse prevention treatment, especially in alcohol-dependent patients with VH DRL.

KW - acamprosate, nalrexone, nalmefene, heavy drinking

KW - alcohol dependence

KW - alcoholism

KW - drinking risk level

KW - gamma-hydroxybutyric acid

KW - GHB

KW - sodium oxybate

UR - http://www.scopus.com/inward/record.url?scp=85049535299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049535299&partnerID=8YFLogxK

U2 - 10.1111/adb.12645

DO - 10.1111/adb.12645

M3 - Article

AN - SCOPUS:85049535299

VL - 23

SP - 969

EP - 986

JO - Addiction Biology

JF - Addiction Biology

SN - 1355-6215

IS - 4

ER -